33rd week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220257666 | METHOD FOR SEPARATING PANCREATIC PROGENITOR CELLS - It is an object of the present invention to provide a method for preparing or separating pancreatic progenitor cells (or a group of pancreatic progenitor cells) that do not contain undifferentiated cells and efficiently differentiate into pancreatic islet cells. More specifically, the present invention relates to: pancreatic progenitor cells that appear in the process of differentiation of stem cells into pancreatic islet cells, which are characterized in that the pancreatic progenitor cells are positive to CD82; an agent for treating blood glucose level impairment, wherein the agent comprises the pancreatic progenitor cells; and a method for preparing pancreatic progenitor cells, wherein the method comprises separating CD82-positive cells. | 2022-08-18 |
20220257667 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity. | 2022-08-18 |
20220257668 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases. | 2022-08-18 |
20220257669 | COMPOSITION AND METHOD FOR PREVENTING, ALLEVIATING, OR TREATING LIVER INJURY - The present invention relates to a composition for preventing, alleviating or treating liver injury, for example, nonalcoholic fatty liver, and more specifically, it relates to a composition for preventing or treating liver injury comprising a | 2022-08-18 |
20220257670 | METHODS AND PRODUCTS FOR TREATMENT OF GASTROINTESTINAL DISORDERS - Described herein are compositions and methods for the delivery of microbial therapeutics useful for the treatment of disorders related to intestinal dysbiosis. | 2022-08-18 |
20220257671 | MAGNETIC BACTERIA, NON-THERAPEUTIC AND THERAPEUTIC USES THEREOF - Recombinant, alive and metabolically active bacteria including a heterologous prokaryotic biomineralized ferritin. In particular, the inventors have shown that naturally non-magnetic | 2022-08-18 |
20220257672 | Compositions for Fecal Floral Transplantation and Methods for Making and Using Them and Devices for Delivering Them - In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or | 2022-08-18 |
20220257673 | METHODS AND PRODUCTS FOR TREATMENT OF GASTROINTESTINAL DISORDERS - Described herein are compositions and methods for the delivery of microbial therapeutics useful for the treatment of disorders related to intestinal dysbiosis. | 2022-08-18 |
20220257674 | SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF - Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human. | 2022-08-18 |
20220257675 | COMPOSITION COMPRISING LACTOCOCCUS CHUNGANGENSIS FOR PREVENTION OR TREATMENT OF FATTY LIVER OR METABOLIC SYNDROME - The present invention relates to a | 2022-08-18 |
20220257676 | AGENT FOR REGULATING FEMALE HORMONE SECRETION AND AGENT FOR ALLEVIATING UNPLEASANT SYMPTOMS - [Problem] The purpose of the present invention is to provide a novel technology capable of regulating female hormone secretion. [Solution] Provided is an agent for regulating female hormone secretion, which contains the | 2022-08-18 |
20220257677 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS - Described herein are methods of generating engineered viral capsid variants. Also described herein are engineered viral capsid variants, engineered viral particles and formulations and cells thereof. Also described herein are vector systems containing an engineered viral capsid polynucleotide and uses thereof. | 2022-08-18 |
20220257678 | RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS (RAAV) HAVING IMPROVED PACKAGING EFFICIENCY - The present invention is directed to recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency, pharmaceutical compositions comprising such rAAV, and methods for their production and use. The present invention is particularly directed to recombinantly-modified adeno-associated virus (rAAV) that have been further modified to comprise Cis-Elements, including replication origins, promoters and enhancers, that are capable of regulating the replication of an rAAV genome and that improve rAAV replication. Preferably, such Cis-Elements are provided within domains of the rAAV that precede and/or follow the 5′ and/or 3′ inverted terminal repeated sequences (ITR) of an rAAV. The invention particularly concerns the presence and the use of polynucleotide Cis-Elements that comprise actual or potential G-Quadruplex Sequences, polynucleotide Cis-Elements that comprise DNA sequences from wild-type AAV (wt AAV) and polynucleotide Cis-Elements that comprise DNA sequences from other viral genomes or from the human genome. | 2022-08-18 |
20220257679 | POLYMER NANOPARTICLE COMPOSITION FOR DELIVERING VIRUS, AND PREPARATION METHOD THEREFOR - The present invention relates to: a virus-containing pharmaceutical composition, which comprises, as an active ingredient, a virus for treating or preventing disease; and a preparation method therefor. | 2022-08-18 |
20220257680 | COMPOUND-CONTAINING COMPOSITION - The present disclosure relates to a composition containing a compound of formula 1 and a compound of formula 2. The present disclosure further relates to compositions containing a compound of formula 1 and a compound of formula 2, and which also contains one or more pharmaceutically acceptable carriers. The compositions may be formulated for oral administration, including as a pill, capsule, or tablet. | 2022-08-18 |
20220257681 | COMPOSITION FOR INCREASING BIOAVAILABILITY AND PROMOTING ABSORPTION OF GINSENOSIDES IN BLACK GINSENG EXTRACT - The present invention relates to a composition for increasing the bioavailability and promoting the absorption of ginsenosides in a black ginseng extract. | 2022-08-18 |
20220257682 | Biochemical Scaffolds for Modulating Cell Function - A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a Krebs cycle modulator and/or glutathione modulator and/or neurotransmitter modulator and/or DNA modulator and/or endocannabinoid system modulator, the vibrational platform comprising at least one energy signature component, e.g., herb, that is subjected to continued or steady state harmonic oscillation at a frequency in the range of approximately 23 Hz-1000 GHz for a period of time in the range of approximately 3-48 hrs. or sequential harmonic oscillation at frequencies in the range of approximately 0.9 kHz-1.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-10.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-11.0 kHz for a period of time in the range of approximately 3-60 minutes, approximately 0.01 kHz-0.03 kHz for a period of time in the range of approximately 3-60 minutes, and approximately 0.004 kHz-0.010 kHz for a period of time in the range of approximately 3-60 minutes. | 2022-08-18 |
20220257683 | METHODS AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE - A method of treating fine lines or wrinkles in a person's skin or treating a person's sagging or loose skin is disclosed. The method can include topically applying to the fine line or wrinkle or to sagging or loose skin an effective amount of a topical composition comprising a | 2022-08-18 |
20220257684 | ANTI-COCCIDIAL PHYTOGENIC FORMULATIONS - The present invention relates to anti-coccidial phytogenic formulations. Specifically, anti-coccidial compositions and use thereof are disclosed. An anti-coccidial composition comprises (a) an effective amount of | 2022-08-18 |
20220257685 | PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES - The invention relates to a composition comprising at least:
| 2022-08-18 |
20220257686 | COMPOSITIONS AND METHODS TO AFFECT HUMAN GUT MICROBES - The present disclosure provides compositions and foods that selectively promote the representation and expressed beneficial function of members of a human gut community in ways that promote a healthy gut microbiota and in turn positively impact health. Various examples of compositions and foods, which comprise one or more fiber preparation, are discussed in detail, as are methods of their use. | 2022-08-18 |
20220257687 | MEMBRANE FILTRATION OF PLANT EXTRACTS BY MEANS OF CYCLODEXTRIN - The present invention relates to a method for producing an alcohol-reduced or alcohol-free composition of at least one alcohol-containing plant extract by means of membrane filtration using cyclodextrin. | 2022-08-18 |
20220257688 | COMPOSITION COMPRISING SALVIA MILTIORRHIZA OR PAEONIA LACTIFLORA EXTRACT AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF LIPID METABOLISM DISORDER - The present invention relates to a composition comprising a | 2022-08-18 |
20220257689 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAIN - This disclosure provides a chewing gum composition comprising an herbal extract and a gum base. The disclosure also provides methods of treating symptoms associated with menopause comprising administering to a subject in need thereof, a gum-based composition for chewing, the composition comprising an herbal extract and a gum base. | 2022-08-18 |
20220257690 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES - The invention provides cyclodextrin inclusion complex delivery vehicles, in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials. | 2022-08-18 |
20220257691 | MEDICINE FOR TREATING PULMONARY MYCOSIS - The application of the addition and subtraction of Er Chen Tang in the preparation of medicine or health care products for the treatment of pulmonary fungal diseases belongs to the medical and health care field, which specifically relates to the use of alkaloids and volatile oils contained in | 2022-08-18 |
20220257692 | COMPOSITIONS AND METHODS FOR SUPPORTING IMMUNE HEALTH - Various embodiments provide a method of increasing immunity to a virus in a subject. The method can comprise: administering to the subject one or more effective doses of an immune-enhancing natural-based composition; thereby stimulating increased expression one or more of IFN-γ, IL-1B, IL-6, IL-10, IL-12p40, IL-12p70, and TNF-α; inhibiting replication of the virus inside a cell of the subject, and preventing entry of virus into the cell. The method of increasing immunity can further comprise increasing immunity to an upper respiratory tract viral infection. The upper respiratory tract viral infection can be COVID-19. According to some aspects of the method of increasing immunity, the effective dose of the immune-enhancing natural-based composition comprises: 30-70 mgs of cyanidin-3-glucosides; 40-80 mgs of andrographolides; 75-125 mgs of ascorbic acid; 400-600 mgs of beta glucans; 300-500 mgs of polysaccharides; and 75-125 mgs of a blend of antioxidants. | 2022-08-18 |
20220257693 | POLYPEPTIDE DIMER WITH HIGH SIALIC ACID CONTENT, COMPRISING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases. | 2022-08-18 |
20220257694 | MIXTURES AND FORMULATIONS - The present invention relates to mixtures comprising:
| 2022-08-18 |
20220257695 | A GNRH ANTAGONIST FOR USE IN THE TREATMENT OF A WOMEN AFFECTED WITH POLYCYSTIC OVARY SYNDROME - The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use to rescue ovulation and fertility in postpuberal PCOS affected individuals. | 2022-08-18 |
20220257696 | Granular Pharmaceutical Composition - The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function. | 2022-08-18 |
20220257697 | INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS - The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy. | 2022-08-18 |
20220257698 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER - The present invention relates to the cyclic peptides that are agonists of the angiotensin II type 2 receptor (hereinafter the AT2 receptor) useful in the treatment of different types of solid cancer, in particular brain, colon, lung and ovarian cancer. The invention further relates to pharmaceutical compositions containing them and uses thereof for the treatment of cancer. | 2022-08-18 |
20220257699 | PHARMACEUTICAL DEVELOPMENT - The present invention relates to a pharmaceutical product in the form of a storage stable lyophilisate or a pharmaceutical formulation in the form of a sterile solution for parenteral administration. Both the lyophilisate and solution consist essentially of a polymyxin selected from polymyxin E, polymyxin B, or a pharmaceutically acceptable derivative thereof, and zidovudine or a pharmaceutically acceptable derivative thereof. The solution further includes an aqueous carrier. | 2022-08-18 |
20220257700 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS - The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain. | 2022-08-18 |
20220257701 | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN TREATING AND PREVENTING CANCER - Provided herein, are methods of identifying neoantigens for treating and preventing cancer. Also disclosed are methods and compositions for administering identified neoantigens for the treatment and prevention of cancer. | 2022-08-18 |
20220257702 | STABLE ALBUVIRTIDE COMPOSITIONS - The present disclosure relates to compositions comprising albuvirtide, an HIV-1 fusion inhibitor, including liquid compositions and stable lyophilized compositions. The present disclosure also provides the manufacturing process thereof and use of the these compositions for the prevention, treatment or prophylaxis of diseases caused by HIV. | 2022-08-18 |
20220257703 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS - The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis. | 2022-08-18 |
20220257704 | COMBINATION OF CHEMOTHERAPY WITH RECOMBINANT S. ROLFSII LECTIN - The present invention relates to the combination chemotherapy with recombinant lectin protein. The invention specifically relates to the cytotoxic effect of recombinant lectin protein having amino acid sequence of SEQ ID NO: 1 in combination with other therapeutic agents, wherein the other therapeutic agents are anti-cancer agents. The combinations are highly synergistic and efficacious against several cancers. | 2022-08-18 |
20220257705 | ACE INHIBITORY PEPTIDE COMPOSITION DERIVED FROM GINKGO PROTEIN AND PREPARATION METHOD AND APPLICATION THEREOF - The present disclosure provides ACE inhibitory peptide composition derived from ginkgo protein and preparation method and application thereof, belonging to the technical field of food and medicine. The ACE inhibitory peptide composition derived from ginkgo protein mainly consists of six small molecular peptides with amino acid sequences of GFDGR (SEQ ID NO. 1), NDPGR (SEQ ID NO. 2), LDQTYRP (SEQ ID NO. 3), REHETIIL (SEQ ID NO. 4), LRMPGPPSSDDY (SEQ ID NO. 5) and LRMPGPPSDDYER (SEQ ID NO. 6). The specific preparation process includes preparation of ginkgo protein, hydrolysis of ginkgo protein, enzymolysis and hydrolysis of ginkgo protein to obtain crude ACE inhibitory peptide, and separation and purification of ACE inhibitory peptide composition derived from ginkgo protein. | 2022-08-18 |
20220257706 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) LIGANDS - The present invention relates to hyper-stable EGFR peptide ligands that are plant-derived, particularly isolated from | 2022-08-18 |
20220257707 | FABRICATION OF PROTEIN-ENCAPSULATING MICROGELS - The present invention provides methods for fabricating protein-encapsulating microgels using hydrocarbon-in-fluorocarbon emulsions. The non-aqueous emulsion-based microgel fabrication methods can be used for the encapsulation of a wide range of proteins and peptides, including antibodies and antibody-fusion proteins, for therapeutic use with ease of administration. | 2022-08-18 |
20220257708 | COMPOSITION FOR PREVENTING, TREATING OR ALLEVIATING DIABETES, COMPRISING LGI3-DERIVED PEPTIDE AS AN ACTIVE INGREDIENT - The present invention relates to a composition and the like, for preventing, treating or alleviating diabetes, comprising an LGI3-derived peptide as an effective component. The composition comprising, as an active ingredient, an LGI3-derived peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 of the present invention exhibits an inhibitory effect on weight gain, elevation of blood glucose levels, pancreas and liver damage, elevation of blood lipid levels, and an increase of insulin resistance indexes accompanied by diabetes and diabetes-associated metabolic disorders associated with diabetes, and thus can prevent, treat, or alleviate diabetes and metabolic disorders associated with diabetes. | 2022-08-18 |
20220257709 | P21 Expressing Monocytes for Cancer Cell Therapy - Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia. | 2022-08-18 |
20220257710 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF - Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present disclosure can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects. | 2022-08-18 |
20220257711 | PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES - NMEG-αCGRP, a biologically active molecule, and systems and methods of use therefore, subcutaneous administration of NMEG-αCGRP, a non-toxic peptoid-peptide hybrid that possesses hypotensive action, employed as a therapeutic agent to treat and prevent various cardiovascular diseases, including, heart failure (pressure. as well as volume, overload), myocardial infarction, cardiomyopathy, and hypertension. | 2022-08-18 |
20220257712 | ANTI-PATHOGEN INTERLEUKIN-TGF-BETA RECEPTOR FUSION POLYPEPTIDES - Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGFβ ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of treating and/or preventing pathogenic infections. | 2022-08-18 |
20220257713 | COMPOUND AND COMPOSITIONS FOR MULTITARGET TREATMENT OF TAU PROTEIN-RELATED DISORDERS - Tau protein misfolding, aggregation and accumulation in the nervous system is an abnormal event which is responsible for widespread synaptic loss and neurodegeneration; it can occur spontaneously or can be triggered by misfolding of amyloid β protein. The present invention concerns the use of hexapeptide Aβ1-6 | 2022-08-18 |
20220257714 | USE OF DERMCIDIN IN STERILE INFLAMMATORY CONDITIONS - A method of treating a sterile inflammatory condition in a subject using an isolated dermcidin peptide or an active fragment thereof of or an active analog thereof is provided. Also provided is a method of inhibiting organ transplantation-associated ischemia/reperfusion and/or organ transplantation-associated inflammation. | 2022-08-18 |
20220257715 | RELEASE OF GROWTH FACTORS AT WOUND HEALING STAGES - The present invention provides collagen-binding agents that can be used to treat wounds, ischemic heart disease, and other conditions. The collagen-binding agents comprise a therapeutic agent, a protease cleavage site, and a collagen-binding domain. The present invention further provides pharmaceutical compositions and biomedical devices comprising the disclosed collagen-binding agents, as well as methods for treating a condition using the collagen-binding agents. | 2022-08-18 |
20220257716 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SECRETORY DISORDERS - The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the prevention of EPI or pancreatitis resulting from surgical procedures. | 2022-08-18 |
20220257717 | Methods of Treatment Using Encapsulated Cells - Provided are methods of treatment comprising administering to a subject in need thereof a therapeutically effective amount of encapsulated cells to an affected tissue or organ. | 2022-08-18 |
20220257718 | SMALL PEPTIDE COMPOSITIONS AND USES THEREOF - Interferon-γ-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C—X—C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed. | 2022-08-18 |
20220257719 | APPETITE SUPPRESSING COMPOUNDS - PYY-derived compounds comprising residues changed from the naturally-occurring peptide sequence and substituted, for example at their gamma-carboxylic acid groups, epsilon-amino groups or alpha-amino groups, with fatty dioic acid groups either directly or via short pendant oligopeptides. Related methods, compositions and uses, in particular for use in appetite suppression and the treatment or prevention of diabetes or obesity | 2022-08-18 |
20220257720 | Modified Relaxin Polypeptides and Their Uses - Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided. | 2022-08-18 |
20220257721 | PHARMACEUTICAL COMPOSITION CONTAINING GLY-THYMOSIN BETA-4 (GLY-TB4) FOR TREATMENT OF DRY EYE - The present invention relates to a pharmaceutical composition for treating dry eye syndrome, which comprises Gly-Tβ4 as an active ingredient, and the pharmaceutical composition restores damaged corneal epithelial cells and also has an effect of proliferating goblet cells, and thus is effective for treating, preventing, or alleviating dry eye syndrome. | 2022-08-18 |
20220257722 | COMPOSITIONS AND METHODS OF TREATING AND PREVENTING SYSTEMIC COMPLICATIONS OF ACUTE ILLNESS - The disclosure relates to compositions and methods of suppressing or preventing systemic organ inflammation or multi organ failure in a human patient with acute illnesses, including but not limited to burns, major surgery, sepsis, autoimmune disorders, vasculitis, thromboembolism, trauma, and acute pancreatitis. The method comprises administering to a patient in need of treatment an effective amount of a glucagon-like peptide-2 or an analog thereof. | 2022-08-18 |
20220257723 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 2022-08-18 |
20220257724 | DI-THIOESTER CATIONIC LIPIDS - The present invention provides, in part, di-thioester cationic lipid compounds or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins. | 2022-08-18 |
20220257725 | COMPOSITIONS AND METHODS FOR TREATING PEROXISOMAL BIOGENESIS DISORDERS - Disclosed herein are compositions and methods for treating mitochondrial dysfunction. The methods can include compositions capable of increasing or overexpressing ATAD1. The methods include restoring mitochondrial respiration and ATP production. The present disclosure provides a mechanism for peroxin (peroxisomal biogenesis factors) accumulation on mitochondria that affects respiration and ATP generation. | 2022-08-18 |
20220257726 | INTESTINAL ALKALINE PHOSPHATASE-BASED TREATMENTS OF METABOLIC DISORDERS - The present invention relates, inter alia, to combination therapies of specific commensal gastrointestinal bacteria with therapeutic intestinal alkaline phosphatases for the treatment of disease, such as metabolic disorders. The present invention further relates to compositions comprising the combination of specific commensal gastrointestinal bacteria with therapeutic alkaline phosphatases and use of the compositions in the treatment of metabolic disorders. | 2022-08-18 |
20220257727 | PHARMACEUTICAL COMPOSITION CONTAINING LYSOZYME AND USE THEREOF - Disclosed are a pharmaceutical composition containing lysozyme and the use thereof in the preventing psoriasis, treating of psoriasis, and/or preventing of psoriasis recurrence. The pharmaceutical composition can significantly prolong the time before disease recurrence and significantly reduce the recurrence rate of diseases compared with the use of traditional oral drugs, immunosuppressive agents, biological agents, etc. | 2022-08-18 |
20220257728 | USE OF HISTONE DEUBIQUITINASE IN PREPARING DRUG FOR PREVENTING AGING AND TREATING AGING-RELATED DISEASES - The present disclosure provides use of a histone deubiquitinase in preparing a drug for preventing aging and treating aging-related diseases and relates to the technical field of biological medicines. The histone H2A deubiquitinase MYSM1 has a nucleotide sequence shown as SEQ ID NO. 1. It is verified that MYSM1 protein deficiency causes significant aging of mice and induces the aging-related diseases; and the MYSM1 can promote DNA injury repair, prevent cellular senescence and suppress chronic inflammation. Proved by a result of using an adeno-associated virus expressing mouse-derived MYSM1 as a gene therapy, the MYSM1 may remarkably prolong the lifespan of the mice, reduce the process and the number of senescent cells, improve normal functions of tissues and organs, reduce occurrence and development of the aging-related diseases, which proves that the MYSM1 has a good application prospect in delaying aging and treating the aging-related diseases. | 2022-08-18 |
20220257729 | COMBINATION OF INTEGRIN-TARGETING KNOTTIN-FC FUSION AND ANTI-CD47 ANTIBODY FOR THE TREATMENT OF CANCER - The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein in combination with an SIRPα-CD47 immune checkpoint inhibitor, for example an anti-CD47 antibody or an anti-SIRPα-antibody. The invention also provides composition for use in such methods. | 2022-08-18 |
20220257730 | BOTULINUM TOXIN TYPE A COMPLEX, AND FORMULATION THEREOF AND USAGE METHOD THEREFOR - The present invention relates to a | 2022-08-18 |
20220257731 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC IMBALANCE IN NEURODEGENERATIVE DISEASE - In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile. | 2022-08-18 |
20220257732 | ENUMERATION OF GENETICALLY ENGINEERED MICROORGANISMS BY LIVE CELL COUNTING TECHNIQUES - Genetically engineered microorganisms, e.g., genetically engineered bacteria, compositions and formulations thereof, as well as methods for characterizing, dosing, and determining the activity of the bacteria, compositions, and formulations, e.g., using a live cell counting method are disclosed. | 2022-08-18 |
20220257733 | ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF - Provided are novel antigenic polypeptides comprising tumor-associated peptides, and compositions comprising the same. Such antigenic polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using the polypeptides and compositions, methods of treating a disease using the polypeptides and compositions, kits comprising the polypeptides and compositions, methods of making the compositions, and antibodies and T cell receptors that specifically bind to the polypeptides. | 2022-08-18 |
20220257734 | ARENAVIRUS PARTICLES AS CANCER VACCINES - The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof. | 2022-08-18 |
20220257735 | A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES - Disclosed are methods for identifying neoantigens and methods of treating cancer using neoantigens identified by said methods. The disclosure herein provide for methods for identifying neoantigens that can be used as a target for the treatment of a cancer, immunize a subject against a cancer, stimulate/induce immune responses, and/or isolate T cells that are reactive to said neoantigens. | 2022-08-18 |
20220257736 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-08-18 |
20220257737 | TUMOR CELL VACCINES - The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens. Also provided herein are methods of making the vaccine compositions, methods of preparing, and methods of use thereof. | 2022-08-18 |
20220257738 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-08-18 |
20220257739 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS - A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule. | 2022-08-18 |
20220257740 | TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL RESPONSES - The present disclosure relates to antigens and methods of generating an immune response for the treatment of cancer. The disclosure also relates to methods of generating MHC-Ia, MHC-II, and/or MHC-E restricted CD8+ T cells for the treatment or prevention of cancer. | 2022-08-18 |
20220257741 | COMBINATION THERAPY FOR CANCER - The present invention relates to a method for the prevention or treatment of cancer in a subject. The method comprises administering to said subject an immunotherapeutic composition comprising a component of an immune system checkpoint, or an immunogenic fragment of said component; and an immunomodulatory agent which blocks or inhibits an immune system checkpoint, which checkpoint may be the same as, or different from, the checkpoint of which the composition comprises a component. The invention also relates to said immunotherapeutic composition and said agent, and to kits comprising same. | 2022-08-18 |
20220257742 | INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO - The application is directed to in vitro-reared | 2022-08-18 |
20220257743 | KLEBSIELLA VACCINE AND METHODS OF USE - Provided are compositions and methods that include a | 2022-08-18 |
20220257744 | IMMUNOGENIC COMPOSITION COMPRISING A FUSION PEPTIDE DERIVED FROM SUPERANTIGEN TOXOIDS - The present disclosure provides immunogenic compositions useful in prevention and treatment of | 2022-08-18 |
20220257745 | COMPOSITIONS COMPRISING OF BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for stimulating the immune system and treating and preventing diseases. | 2022-08-18 |
20220257746 | TROPICAL DISEASE VACCINES - The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease. | 2022-08-18 |
20220257747 | METHODS AND COMPOSITIONS OF ASTROVIRUS REPLICONS - The present invention provides recombinant replicons and methods of their use for expression of a secreted protein of interest so as to induce an enhanced immune response. | 2022-08-18 |
20220257748 | HEPATITIS B VIRUS-SPECIFIC T CELL RESPONSES - The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and/or MHC-II restricted CD8 | 2022-08-18 |
20220257749 | INFLUENZA VIRUS HEMAGGLUTININ PROTEINS AND USES THEREOF - Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject. | 2022-08-18 |
20220257750 | PROTEOLYSIS-TARGETING VIRUS, LIVE VACCINE THEREOF, PREPARATION METHOD AND USE THEREOF - Provided is a proteolysis-targeting virus, wherein one or more proteolysis-targeting molecules that can be recognized by the ubiquitin-proteasome system are comprised at one or more different sites of protein thereof, and the viral protein is linked to the proteolysis-targeting molecules by one or more linkers that can be selectively cleaved. Also provided are a nucleic acid molecule encoding the proteolysis-targeting virus, a nucleic acid vector expressing the proteolysis-targeting virus, a preparation method for the proteolysis-targeting virus, methods for the preparation of an attenuated live virus, replication-incompetentlive virus, replication-controllable live virus, and a relevant vaccine and medication for preventing and treating virus infections, a vaccine or pharmaceutical composition comprising the proteolysis-targeting virus, and a system for preparing the proteolysis-targeting virus. | 2022-08-18 |
20220257751 | QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION - The present invention provides analytical tools for the characterisation of bioconjugates, in particular for the measurement of glycosylation levels, and methods for absolute quantification of glycosylation sequences, as well as sequences and glycosylation sites for use in such methods. | 2022-08-18 |
20220257752 | NEW USE OF CYCLIC DINUCLEOTIDES - In a first aspect, the present invention relates to cyclic dinucleotide compounds, in particular, c-di AMP for use in a method of inducing or promoting an immune response in an individual wherein said individual is a neonate or infant. The compound according to the present invention is particularly useful for use in therapeutic or prophylactic vaccination. In a further aspect, pharmaceutical compositions comprising the compound according to the present invention as an adjuvant, a pharmaceutically active ingredient for use as defined herein, in particular, as an adjuvant in a vaccine for unborn children, neonates and infants are provided. Finally, the present invention relates to a kit comprising a compound according to the present invention as an adjuvant, an antigen comprising antigenic structure as active vaccination component, in particular, to the use of said kit in a use of preventing or treating a disease. | 2022-08-18 |
20220257753 | Vaccine Adjuvants for Antigen Delivery - Cellulose nanoparticle formulations, containing cellulose nanocrystals or nanofibrils, for use as vaccine adjuvants and/or as antigen delivery systems, and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. Cellulose nanoparticle formulations demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents. Further identification of physical and chemical properties of the cellulose nanoparticle formulations can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo. Relating to the use of the formulations in the treatment of diseases of humans and animals. | 2022-08-18 |
20220257754 | FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE - Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided. | 2022-08-18 |
20220257755 | COMBINATION THERAPY FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of T-cells that are used in combination with antagonists of the cytokine CXCL10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1. | 2022-08-18 |
20220257756 | ENGINEERED VACCINIA VIRUS - An engineered vaccinia virus, a pharmaceutical composition containing the same, and methods for use in treating a subject in need using the same are provided. The engineered vaccinia virus includes a mutated viral sequence and a heterologous sequence. The mutated viral sequence is used for selective replication in tumor cells and/or activation of immune cells. The heterologous sequence encodes an immune co-stimulatory pathway activating molecule, immunomodulator gene, a truncated viral envelope gene, and/or a tumor suppressor. The heterologous sequence is stably incorporated into the genome of the engineered vaccinia virus. The pharmaceutical composition includes an effective amount of the engineered vaccinia virus and a pharmaceutical acceptable vehicle. The methods for use in treating the subject in need include administering the engineered vaccinia virus to the subject. | 2022-08-18 |
20220257757 | METHOD FOR PRECONDITIONING A SUBJECT WHO IS ABOUT TO RECEIVE A T-CELL THERAPY - The present invention provides a method for preconditioning a subject who is about to receive a therapeutic T-cell composition, which comprises the step of administering one or more doses of a checkpoint inhibitor to the subject prior to administration of the therapeutic T-cell composition, wherein the subject does not receive any further doses of the checkpoint inhibitor after administration of the therapeutic T-cell composition. | 2022-08-18 |
20220257758 | METHODS OF ADMINISTERING ANTI-SIGLEC-8 ANTIBODIES AND CORTICOSTEROIDS - The present disclosure provides methods and kits suitable for administering a composition comprising an antibody that binds to human Siglec-8, e.g., to a human individual in need thereof. In some embodiments, a corticosteroid is administered to the individual at least 6 hours, at least 12 hours, or 12-24 hours prior to the first dose of the composition comprising the anti-Siglec-8 antibody. | 2022-08-18 |
20220257759 | TREATMENT OF SARCOMA USING IMMUNOMODULATION - The present disclosure provides a method for treating a subject afflicted with sarcoma selected from soft tissue sarcoma (such as liposarcoma, myxoid sarcoma) and osteosarcoma by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab, wherein Talabostat or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.3 mg twice daily on one or more days of a treatment cycle. | 2022-08-18 |
20220257760 | CANCER-TARGETED, VIRUS-ENCODED, REGULATABLE T (CATVERT) OR NK CELL (CATVERN) LINKERS - Recombinant polynucleotides and vectors containing an engineered (artificial) exon-intron-exon gene structure in a transgene are provided, which undergoes splicing when it is expressed in a target cell. | 2022-08-18 |
20220257761 | THERAPEUTIC COMPOSITION AND METHOD COMBINING MULTIPLEX IMMUNOTHERAPY WITH CANCER VACCINE FOR THE TREATMENT OF CANCER - This invention relates to a therapeutic composition comprising i) at least two immune checkpoint inhibitors, ii) at least one drug selected from a cytokine a cytotoxic or cytostatic chemotherapeutic drug, and combinations thereof, and iii) a cancer vaccine prepared from tumor or cancer cells, or derivatives thereof, that have been prepared through an ex vivo treatment that creates necrotic and/or necroptotic cancer cells while minimizing destruction of cancer antigens. This invention also relates to a method of treating a tumor or a cancer in a patient comprising administering to a patient in need thereof the therapeutic composition in an amount effective to treat the tumor or cancer. | 2022-08-18 |
20220257762 | ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS - The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention. | 2022-08-18 |
20220257763 | ROOM TEMPERATURE STABLE LYOPHILIZED PROTEIN - Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of post-drying annealing under certain conditions improves protein stability. Proteins are predicted to remain stable over 24 months at 25° C. | 2022-08-18 |
20220257764 | USE OF DIKETONE COMPOUND IN PHOTODYNAMIC THERAPY OR DIAGNOSIS - The disclosure belongs to the technical field of medicine, and relates to use of a diketone compound in photodynamic therapy or diagnosis. Particularly, the disclosure relates to use of a compound of formula (I), pharmaceutically acceptable salt or ester, prodrug, stereoisomer, hydrate, solvate or crystal form of the compound, metabolite of each of them, or any combination or mixture thereof in preparation of a drug or a reagent. The drug or the reagent is used for photodynamic therapy or photodynamic diagnosis of a disease or is used for skin beauty by means of photodynamic therapy. | 2022-08-18 |
20220257765 | TARGET-SPECIFIC CONJUGATE AND USE THEREFOR - An object is to provide a novel therapeutic strategy that solves the problems involved in antibody drug conjugates (ADCs), and that can provide high therapeutic effects. Provided is a photodynamic pharmacotherapy using a target-specific conjugate containing a molecule specifically bindable to a target molecule, a drug, and a substance sensitive to near-infrared light, wherein the drug and the substance sensitive to near-infrared light are linked to the specifically bindable molecule. | 2022-08-18 |